TRIM44 and Miyoshi myopathy: However, the addition of 3-Methyladenine (3-MA), an inhibitor that blocks autophagosome formation by inhibiting the class III PI3K complex, mitigated this effect (Figure 4F), highlighting TRIM44’s role in autophagy-mediated survival enhancement in MM cells treated with Bortezomib.